Darbepoetin as a Neuroprotective Agent in Mild Neonatal Encephalopathy: A Randomized, Placebo Controlled, Feasibility Trial

OBJECTIVE: To assess the feasibility and safety of one dose of Darbepoetin alpha (Darbe) administered to neonates ≥34 weeks with mild neonatal encephalopathy (NE) METHODS: Randomized, masked, placebo-controlled study including neonates ≥34 weeks gestation with mild NE. Neonates were randomized to re...

Descripción completa

Detalles Bibliográficos
Autores principales: DuPont, Tara L, Baserga, Mariana, Lowe, Jean, Zamora, Tara, Beauman, Sandra, Ohls, Robin K
Formato: Online Artículo Texto
Lenguaje:English
Publicado: 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8238874/
https://www.ncbi.nlm.nih.gov/pubmed/33986477
http://dx.doi.org/10.1038/s41372-021-01081-y

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8238874/
https://www.ncbi.nlm.nih.gov/pubmed/33986477
http://dx.doi.org/10.1038/s41372-021-01081-y

Ejemplares similares